Older, younger patients with metastatic pancreatic cancer have similar survival
the ONA take:
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy and receive fewer agents yet have similar overall survival compared with younger patients with metastatic disease, according to a recent study published online ahead of print in the Journal of Geriatric Oncology.
For the study, researchers at Fox Chase Cancer Center in Philadelphia, PA, sought to compare patterns of care and outcomes of patients with metastatic pancreatic cancer who are less than 65 years of age with those older than 65 years of age treated at their institution.
The researchers analyzed the medical records of 579 patients who were treated between 2000 and 2010. Results showed that patients older than 65 years were less likely to receive any chemotherapy for their cancer. In addition, those over 65 who were treated were less likely to receive more than 1 agent.
Researchers found that survival was comparable between the two cohorts. In both groups, a higher number of treatment agents and lung metastatases was associated with longer overall survival, while liver metastates were associated with worse survival.
The findings suggest that older patients with metastatic pancreatic cancer with good performance status should be encouraged to enroll onto clinical trials.
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy compared with younger patients with metastatic disease.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|